|Brief Description||Principal Investigator|
|The primary objective of this study is to evaluate safety and tolerability and select a recommended Phase 2 dose (RP2D) of ADXS31-164 in subjects with solid tumors that express HER2||Tan, Antoinette Roslyn|
The primary objectives are as follows:
To evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of AGEN1884 in subjects with advanced or metastatic cancer (solid tumors or lymphoma) including but not limited to carcinoma, sarcoma, malignant glioma, or melanoma.
To determine the maximum tolerated dose (MTD).
To evaluate the pharmacokinetics (PK) of AGEN1884 in subjects with advanced or
metastatic solid tumors.
|Hwang, Jimmy John|
|To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug.||Kim, Edward Sanghyun|
|In the neoadjuvant cohort, to investigate the safety and tolerability of neoadjuvant nivolumab administration in the following tumor types: HPV-positive (SCCHN), HPV-negative (SCCHN), Merkel Cell Carcinoma, Cervical, vaginal, or vulvar cancers. In the metastatic/recurrent cohort, to evaluate the investigator-assessed objective response rate (ORR) of nivolumab monotherapy and combination therapy of Nivolumab and Ipilimumab in subjects with the following diseases: Metastatic or recurrent nasophary||Amin, Asim|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
|Estimate PFS in previously untreated mCRC patients receiving FOLFIRI + bevacizumab when irinotecan dose is based on UGT1A1 genotype||Patel, Jai Narendra|
-To determine the RP2D of LY2606368 and ralimetinib used in combination that may be safely administered to patients with advanced cancer
-Evaluate safety and tolerability of LY2606368 in combination with ralimetinib
|Hwang, Jimmy John|
|To identify subpopulations of registry patients on the basis of their molecular profiles that may be eligible for participation in available NSABP clinical trials involving novel agents.||Hwang, Jimmy John|